The Wayback Machine - https://web.archive.org/web/20120217090320/http://en.wikipedia.org/wiki/TC-5619

TC-5619

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TC-5619
Systematic (IUPAC) name
N-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code  ?
PubChem CID 16727410
UNII UM3821998K YesY
Chemical data
Formula C22H23N3O2 
Mol. mass 361.437
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

TC-5619 is a drug developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia.[1] Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound. [3]

[edit] References


Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Morty Proxy This is a proxified and sanitized view of the page, visit original site.